Neuren Pharmaceuticals

Date of inclusion: 10 March 2021
Share price on inclusion: $1.255

Date of exclusion: 25 August 2021
Share price on exclusion: $2.24

 

Neuren has performed well since we included it in Marc and Stuart’s Top Picks list on 10 March 2021, rising 78.5%. We like the potential of this company to revolutionise the treatment of rare neurological disorders with its trofinenide drug. The Phase 2 data in Rett Ryndrome looked good and the company secured Acadia Pharmaceuticals (Nasdaq: ACAD) ...

Save $$$
30-Day Free Trial
$0
No Credit Card Required!
Get access to 4 publications
Weekly Investor Webinar
Access to Marc & Stuart's Top Picks
Profit Premium
$69
Get access to 4 publications
Access to the full research Archive
Weekly Investor Webinar
Access to Marc & Stuart's Top Picks
30-Day Free Trial
$0
No Credit Card Required!
Get access to 4 publications
Weekly Investor Webinar
Access to Marc & Stuart's Top Picks
Profit Premium
$59
BILLED ANNUALLY
Get access to 4 publications
Access to the full research Archive
Weekly Investor Webinar
Access to Marc & Stuart's Top Picks